Cargando…
Cancer Cells Acquire Mitotic Drug Resistance Properties Through Beta I-Tubulin Mutations and Alterations in the Expression of Beta-Tubulin Isotypes
BACKGROUND: Anti-mitotic compounds (microtubule de-stabilizers) such as vincristine and vinblastine have been shown clinically successful in treating various cancers. However, development of drug-resistance cells limits their efficacies in clinical situations. Therefore, experiments were performed t...
Autores principales: | Cheung, Chun Hei Antonio, Wu, Su-Ying, Lee, Tian-Ren, Chang, Chi-Yen, Wu, Jian-Sung, Hsieh, Hsing-Pang, Chang, Jang-Yang |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2933234/ https://www.ncbi.nlm.nih.gov/pubmed/20838440 http://dx.doi.org/10.1371/journal.pone.0012564 |
Ejemplares similares
-
The mammalian beta-tubulin repertoire: hematopoietic expression of a novel, heterologous beta-tubulin isotype
Publicado: (1986) -
Differential utilization of beta-tubulin isotypes in differentiating neurites
Publicado: (1989) -
Kinetically Stabilizing Mutations in Beta Tubulins Create Isotype-Specific Brain Malformations
por: Park, Kristen, et al.
Publicado: (2021) -
In vivo microtubules are copolymers of available beta-tubulin isotypes: localization of each of six vertebrate beta-tubulin isotypes using polyclonal antibodies elicited by synthetic peptide antigens
Publicado: (1987) -
Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells.
por: Ranganathan, S., et al.
Publicado: (1998)